PharmGen Science
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
PharmGen Science makes prescription medicines, including digestive-system treatments, as well as over-the-counter drugs and obesity treatments, and supplies health-functional foods and beauty products to consumers.
Its products reach patients and end-users through prescription channels and general retail. Listed on KOSPI, Korea's main stock exchange, the company operates three distinct segments: pharmaceuticals, healthcare (functional foods and beauty), and property rental income from a building it owns in Seoul.
Summary is AI-generated and may contain errors · figures from DART filings
The company owns and operates its own building, the PharmGen Science Building in Seoul's Bangbae-dong district, generating rental income as a secondary business alongside its core pharmaceutical operations.
PharmGen Science in five facts
What does PharmGen Science do?
PharmGen Science makes prescription medicines, including digestive-system treatments, as well as over-the-counter drugs and obesity treatments, and supplies health-functional foods and beauty products to consumers.
Where is PharmGen Science listed and in which sector?
PharmGen Science (Korean name: 팜젠사이언스) trades under KRX code 004720 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is PharmGen Science?
Its market capitalisation was US$47.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were PharmGen Science's latest annual revenue and operating profit?
For fiscal year 2025, PharmGen Science reported revenue of US$130.6M, operating profit of US$4.5M and a net loss of US$88M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 1.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.